ProQR Therapeutics NV
NASDAQ:PRQR

Watchlist Manager
ProQR Therapeutics NV Logo
ProQR Therapeutics NV
NASDAQ:PRQR
Watchlist
Price: 2.3 USD 4.55% Market Closed
Market Cap: 242m USD
Have any thoughts about
ProQR Therapeutics NV?
Write Note
Section:
 

Relative Value

The Relative Value of one PRQR stock under the Base Case scenario is 0.97 USD. Compared to the current market price of 2.3 USD, ProQR Therapeutics NV is Overvalued by 58%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PRQR Relative Value
Base Case
0.97 USD
Overvaluation 58%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

10.8
P/S
P/S
Price to Sales
10.8
vs History
85
vs Industry
50
Median 3Y
15.2
Median 5Y
20.1
Industry
7.3
Forward
11.8
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-4.5
Median 5Y
-5.2
Industry
23.3
Forward
-5.1
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
12
Median 3Y
-3.8
Median 5Y
-4.3
Industry
19.8
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
10
Median 3Y
-3.2
Median 5Y
-4.2
Industry
22.6
More Details
2.7
P/B
P/B
Price to Book Value
2.7
vs History
60
vs Industry
15
Median 3Y
2.7
Median 5Y
3.1
Industry
2.7
More Details
4.6
EV/S
EV/S
Enterprise Value to Sales
4.6
vs History
60
vs Industry
56
Median 3Y
3.8
Median 5Y
6.1
Industry
7.6
Forward
5
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.4
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
33
Median 3Y
-1.7
Median 5Y
-2.5
Industry
4.7
Forward
-1.7
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
32
Median 3Y
-1.6
Median 5Y
-2.3
Industry
4.8
Forward
-2.2
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
14
Median 3Y
-1.4
Median 5Y
-2.1
Industry
5.3
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
11
Median 3Y
-1.3
Median 5Y
-2.1
Industry
3.8
More Details
4.8
EV/IC
EV/IC
Enterprise Value to IC
4.8
vs History
39
vs Industry
31
Median 3Y
2.2
Median 5Y
3.2
Industry
5
More Details

Multiples Across Competitors

PRQR Competitors Multiples
ProQR Therapeutics NV Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NL
ProQR Therapeutics NV
NASDAQ:PRQR
247.7m USD 10.8 -7 -2.9 -2.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 841 650.5 -160 844.3 -195 316.3 -193 087.6
US
Abbvie Inc
NYSE:ABBV
336.7B USD 5.9 81 15.4 22.8
US
Amgen Inc
NASDAQ:AMGN
159.4B USD 4.7 26.9 14.4 23.8
US
Gilead Sciences Inc
NASDAQ:GILD
141B USD 4.9 23.6 10.3 14.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.1B USD 11.1 -124.5 26.5 27.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 081.7 -531.2 -578.4 -563
AU
CSL Ltd
ASX:CSL
117B AUD 5 27.8 17.2 21.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.8B USD 4.2 13.3 11.9 13.3
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.5 -66.3 -59.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
41.8B USD 17.8 -155 -695.4 -348.5
P/S Multiple
Revenue Growth P/S to Growth
NL
ProQR Therapeutics NV
NASDAQ:PRQR
Average P/S: 3 076 710.6
10.8
-23%
N/A
FR
Pharnext SCA
OTC:PNEXF
33 841 650.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.9
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.1
10%
1.1
US
E
Epizyme Inc
F:EPE
2 081.7
N/A N/A
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.2
4%
1.1
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17.8
29%
0.6
P/E Multiple
Earnings Growth PEG
NL
ProQR Therapeutics NV
NASDAQ:PRQR
Average P/E: 34.5
Negative Multiple: -7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 844.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.6
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -124.5 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.2 N/A N/A
AU
CSL Ltd
ASX:CSL
27.8
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.3
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.5 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -155 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NL
ProQR Therapeutics NV
NASDAQ:PRQR
Average EV/EBITDA: 15.9
Negative Multiple: -2.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 316.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.5
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.4 N/A N/A
AU
CSL Ltd
ASX:CSL
17.2
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.9
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -695.4 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NL
ProQR Therapeutics NV
NASDAQ:PRQR
Average EV/EBIT: 20.6
Negative Multiple: -2.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 087.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.8
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.8
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
14.1
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.8
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563 N/A N/A
AU
CSL Ltd
ASX:CSL
21.5
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.3
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -348.5 N/A N/A

See Also

Summary
PRQR intrinsic value, competitors valuation, and company profile.
DCF Valuation
PRQR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PRQR stock valuation using valuation multiples.
Wall Street Estimates
PRQR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PRQR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 266,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.